A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
Th1169 details |
| Primary information | |
|---|---|
| ID | 1705 |
| ThPP ID | Th1169 |
| Therapeutic Peptide/Protein Name | Beractant |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | Ia |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 20–30 h. |
| Description | Beractant is a pulmonary surfactant made from natural bovine lung extract. |
| Indication/Disease | Beractant is indicated for Respiratory Distress Syndrome (RDS) in premature infants. |
| Pharmacodynamics | Endogenous pulmonary surfactant lowers surface tension on alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures. Deficiency of pulmonary surfactant causes Respiratory Distress Syndrome (RDS) in premature infants. SURVANTA replenishes surfactant and restores surface activity to the lungs of these infants. |
| Mechanism of Action | It reproducibly lowers minimum surface tension to less than 8 dynes/cm as measured by the pulsating bubble surfactometer and Wilhelmy Surface Balance. |
| Toxicity | NA |
| Metabolism | Surfactant is recycled and metabolized exclusively in the lungs. |
| Absorption | Absorbed from the alveolus into lung tissue, where it can be extensively catabolized and reutilized for further phospholipid synthesis and secretion. Onset: 0.5–4 h. Peak: 2 h. Duration: 48–72 h; may need multiple doses to sustain improvement. |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Bretylium may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ceritinib; Esmolol may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ivabradine; Beractant may increase the atrioventricular blocking (AV block) activities of Lacosamide; Octreotide may increase the bradycardic activities of Beractant; Ruxolitinib may increase the bradycardic activities of Beractant; Tofacitinib may increase the bradycardic activities of Beractant. |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | NA |
| Company | NA |
| Brand Discription | NA |
| Prescribed for | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physcial Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | pale skin; slow heartbeat; breathing that stops; urinating less than usual; or blood in the urine; noisy breathing; feeding or bowel problems; or bleeding around the endotracheal tube. |
| Useful Link | http://www.rxlist.com/survanta-drug/clinical-pharmacology.htm; http://www.robholland.com/Nursing/Drug_Guide/data/monographframes/B018.html |
| PubMed ID | 17533176, 15813666 |
| 3-D Structure | N.A. |
| Primary information | |
|---|---|
| ID | 1706 |
| ThPP ID | Th1169 |
| Therapeutic Peptide/Protein Name | Beractant |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | Ia |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 20–30 h. |
| Description | Beractant is a pulmonary surfactant made from natural bovine lung extract. |
| Indication/Disease | Beractant is indicated for Respiratory Distress Syndrome (RDS) in premature infants. |
| Pharmacodynamics | Endogenous pulmonary surfactant lowers surface tension on alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures. Deficiency of pulmonary surfactant causes Respiratory Distress Syndrome (RDS) in premature infants. SURVANTA replenishes surfactant and restores surface activity to the lungs of these infants. |
| Mechanism of Action | In vitro, SURVANTA reproducibly lowers minimum surface tension to less than 8 dynes/cm as measured by the pulsating bubble surfactometer and Wilhelmy Surface Balance. In situ, SURVANTA restores pulmonary compliance to excised rat lungs artificially made surfactantdeficient. In vivo, single SURVANTA doses improve lung pressure-volume measurements, lung compliance, and oxygenation in premature rabbits and sheep. |
| Toxicity | NA |
| Metabolism | Surfactant is recycled and metabolized exclusively in the lungs. |
| Absorption | Absorbed from the alveolus into lung tissue, where it can be extensively catabolized and reutilized for further phospholipid synthesis and secretion. Onset: 0.5–4 h. Peak: 2 h. Duration: 48–72 h; may need multiple doses to sustain improvement. |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Bretylium may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ceritinib; Esmolol may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ivabradine; Beractant may increase the atrioventricular blocking (AV block) activities of Lacosamide; Octreotide may increase the bradycardic activities of Beractant; Ruxolitinib may increase the bradycardic activities of Beractant; Tofacitinib may increase the bradycardic activities of Beractant. |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Survanta |
| Company | Abb Vie Inc. |
| Brand Discription | SURVANTA ® (beractant) Intratracheal Suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural bovine lung extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins to which colfosceril palmitate (dipalmitoylphosphatidylcholine), palmitic acid, and tripalmitin are added to standardize the composition and to mimic surface-tension lowering properties of natural lung surfactant. |
| Prescribed for | SURVANTA is indicated for prevention and treatment (“rescueâ€) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. SURVANTA significantly reduces the incidence of RDS, mortality due to RDS and air leak complications. |
| Chemical Name | NA |
| Formulation | 25 mg/mL |
| Physcial Appearance | Suspension |
| Route of Administration | endotracheal |
| Recommended Dosage | Each dose of SURVANTA is 100 mg of phospholipids/kg birth weight (4 mL/kg). |
| Contraindication | NA |
| Side Effects | pale skin; slow heartbeat; breathing that stops; urinating less than usual; or blood in the urine; noisy breathing; feeding or bowel problems; or bleeding around the endotracheal tube. |
| Useful Link | |
| PubMed ID | 17533176, 15813666 |
| 3-D Structure | N.A. |
| Primary information | |
|---|---|
| ID | 1707 |
| ThPP ID | Th1169 |
| Therapeutic Peptide/Protein Name | Beractant |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | Ia |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 20–30 h. |
| Description | Beractant is a pulmonary surfactant made from natural bovine lung extract. |
| Indication/Disease | Beractant is indicated for Respiratory Distress Syndrome (RDS) in premature infants. |
| Pharmacodynamics | Endogenous pulmonary surfactant lowers surface tension on alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures. Deficiency of pulmonary surfactant causes Respiratory Distress Syndrome (RDS) in premature infants. SURVANTA replenishes surfactant and restores surface activity to the lungs of these infants. |
| Mechanism of Action | In vitro, SURVANTA reproducibly lowers minimum surface tension to less than 8 dynes/cm as measured by the pulsating bubble surfactometer and Wilhelmy Surface Balance. In situ, SURVANTA restores pulmonary compliance to excised rat lungs artificially made surfactantdeficient. In vivo, single SURVANTA doses improve lung pressure-volume measurements, lung compliance, and oxygenation in premature rabbits and sheep. |
| Toxicity | NA |
| Metabolism | Surfactant is recycled and metabolized exclusively in the lungs. |
| Absorption | Absorbed from the alveolus into lung tissue, where it can be extensively catabolized and reutilized for further phospholipid synthesis and secretion. Onset: 0.5–4 h. Peak: 2 h. Duration: 48–72 h; may need multiple doses to sustain improvement. |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Bretylium may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ceritinib; Esmolol may increase the bradycardic activities of Beractant; Beractant may increase the bradycardic activities of Ivabradine; Beractant may increase the atrioventricular blocking (AV block) activities of Lacosamide; Octreotide may increase the bradycardic activities of Beractant; Ruxolitinib may increase the bradycardic activities of Beractant; Tofacitinib may increase the bradycardic activities of Beractant. |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Survanta |
| Company | Abbvie Corporation |
| Brand Discription | SURVANTA ® (beractant) Intratracheal Suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural bovine lung extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins to which colfosceril palmitate (dipalmitoylphosphatidylcholine), palmitic acid, and tripalmitin are added to standardize the composition and to mimic surface-tension lowering properties of natural lung surfactant. |
| Prescribed for | SURVANTA is indicated for prevention and treatment (“rescueâ€) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. SURVANTA significantly reduces the incidence of RDS, mortality due to RDS and air leak complications. |
| Chemical Name | NA |
| Formulation | 25 mg |
| Physcial Appearance | Suspension |
| Route of Administration | intratracheal |
| Recommended Dosage | Each dose of SURVANTA is 100 mg of phospholipids/kg birth weight (4 mL/kg). |
| Contraindication | NA |
| Side Effects | pale skin; slow heartbeat; breathing that stops; urinating less than usual; or blood in the urine; noisy breathing; feeding or bowel problems; or bleeding around the endotracheal tube. |
| Useful Link | |
| PubMed ID | 17533176, 15813666 |
| 3-D Structure | N.A. |